

Polaroid Therapeutics Announces Strategic Hire: Markus Rothmaier Takes Helm of Research and Development



Markus Rothmaier, Head of Research and Development at Polaroid Therapeutics

BERN, SWITZERLAND, 17 April 2024: Polaroid Therapeutics, a Swiss-based biotech start-up, today announces the appointment of Markus Rothmaier as its inaugural Head of Research and Development (R&D). With over two decades of pharmaceutical R&D leadership experience, Rothmaier will drive product development, strategic partnerships and propel Polaroid Therapeutics' revolutionary anti-microbial technologies forward.

In his new role, Rothmaier will lead Polaroid Therapeutics' strategic direction, and product development, overseeing and leading the company's team of engineers and scientists in their mission to develop new and innovative antimicrobial products and solutions. His extensive experience in drug discovery, notably in his previous roles at IVF Hartmann AG where he specialized in the development of antimicrobial wound dressings and Tactical Combat Casualty Care (TCCC) products, will be instrumental in accelerating Polaroid Therapeutic's mission in combatting AMR (antimicrobial resistance), one of the top 10 global health threats.¹

On Rothmaier's appointment, Ran Frenkel, CEO and co-founder of Polaroid Therapeutics, says, "Markus Rothmaier is joining Polaroid Therapeutics at a critical and exciting time. We welcome

¹ [World Health Organisation](#)



his world-class experience and proven track record of driving the development of novel therapies and bringing transformative treatments to patients in need.”

Markus Rothmaier adds; "I am honored to join Polaroid Therapeutics at such a pivotal moment in the company's start-up journey. The opportunity to contribute to the pipeline of cutting-edge antimicrobial technologies that have the potential to address urgent global health challenges is incredibly inspiring. I look forward to establishing a network of industry-leading partners to translate innovative science into tangible solutions that make a meaningful impact."

Anne Graham, COO and co-founder of Polaroid Therapeutics, added, "Markus's appointment represents a significant milestone for Polaroid Therapeutics as we continue to expand our leadership team and accelerate our product development. His wealth of experience and strategic vision underscores our commitment to building a world-class team of experts dedicated to developing groundbreaking therapies that address unmet medical needs and improve patient outcomes."

ENDS

Notes to Editor

About Polaroid Therapeutics:

Polaroid Therapeutics is a Swiss-based biotech start-up in the development of innovative antimicrobial technology. Incubated and spun off by Polaroid, the brand that pioneered the chemistry behind analogue instant photography. Polaroid Therapeutics' mission is to bring to life the best of Polaroid's vision of creating a more human and meaningful world through cutting-edge technology and research.

Founded in 2022, Polaroid Therapeutics is developing antimicrobial therapies based on proprietary antibacterial technology to prevent and inhibit infections in multiple indications, such as acute and chronic wounds. This unique technology is a breakthrough solution that does not create antimicrobial resistance (AMR) - regarded as the most prominent global threat to health.

Contact:

Abigail Carrigan

polaroidTX@ragency.com